Trellis collaborates with various research organizations and institutions to demonstrate the characteristics and efficacy of its monoclonal antibody candidates. Below is a selection of the company's published research:

"CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them"

January 13, 2020

"(BOSTON, MA) – CARB-X is awarding Trellis Bioscience, of Redwood City, California, USA, up to $3.2 million in non-dilutive funding, with the possibility of $3.8 million more if certain project milestones are met, to develop an innovative monoclonal antibody designed to disrupt the protective biofilm that makes bacteria resistant to antibiotics. With the biofilm coating compromised, the bacteria are more vulnerable to being eliminated by existing antibiotics and by the body’s own immune system. The CARB-X award will support antibody manufacturing for Phase 1.

“Drug-resistant bacterial infections kill hundreds of thousands of people each year around the world, and CARB-X is supporting the development of urgently needed new products to address this crisis,” said Erin Duffy, Chief of Research and Development of CARB-X, which is based at the Boston University School of Law. “The Trellis project is in early development but if successful and approved for use in patients, its promise for tackling challenging, biofilm-mediated infections including joint implants could be transformational for the success of many modern- medical procedures.

“We are thankful that CARB-X is supporting the development of this innovative antibody. We believe it has the potential to be a game-changer in the treatment of a broad range of drug- resistant bacterial infections,” said Stefan Ryser, CEO of Trellis. “CARB-X funding will support the manufacture of the drug for clinical development and, in a potential second tranche of funding, support an initial trial in patients with an infected implant, a type of infection that is particularly hard to treat due to biofilm formation on the surface of the implant.” TRL1068, a native human monoclonal antibody, disrupts the bacterial biofilm by extracting a key scaffolding protein, thereby rendering the bacteria more susceptible to attack by the immune system as well as more sensitive to conventional antibiotics. TRL1068 has been shown to enhance antibiotic activity in highly-drug-resistant strains of Gram-positive and Gram- negative bacteria. The antibody was developed using Trellis’ platform technology, which integrates computerized microscopy with advanced nanomaterials for discovery of native human monoclonal antibodies directly from white blood cells of healthy blood donors."

Read the full press release.

Trellis Bioscience CellSpot Technology Featured at LakePharma Protein Engineering Symposium

October 6, 2017

On Friday, October 6, 2017, Lake Pharma hosted its third annual Antibody Engineering Symposium. Trellis Bioscience was in attendance, along with 400 scientists from various biotechnology organizations and institutions, including AbbVie, BMS, Pfizer, Genetech, and UCSF.

Source Link:

CMC Biologics, Trellis Bioscience in Development and Mfg. Pact

July 26, 2017

"CMC ICOS Biologics, Inc., a clinical and commercial manufacturer of monoclonal antibodies and other therapeutic proteins, and Trellis Bioscience LLC, a private, therapeutic antibody company, have entered into a manufacturing agreement for the process development and production of two of Trellis’ monoclonal antibodies (mAbs). Trellis is developing human mAb therapies for bacterial and viral infections, and cancer indications, and has selected CMC Biologics to work with on two of these products. One is for the treatment of respiratory syncytial virus (RSV) infections that aims to provide superior post-infection treatment over the currently marketed mAb by combining antiviral and anti-inflammatory activity. The other is a first-in-class treatment for drug-resistant bacterial infections due to formation of bacterial biofilms, which works by disrupting the biofilm to resensitize bacteria to conventional antibiotics, with activity spanning Gram-positive to Gram-negative bacterial species, including MRSA and Acinetobacter baumanni. CMC Biologics will utilize its CHEF1 Expression System platform. 'We believe that we have chosen an outstanding CDMO to work with,” said Stefan Ryser, Ph.D., chief executive officer of Trellis Bioscience. “In addition, through their use of Multi-column Continuous Chromatography technology, where a reduced quantity of costly chromatography resins is required in the downstream process, CMC Biologics is able to provide Trellis, a significant reduction in our development and manufacturing costs.' "

Source Link: